Amplex AB becomes the owner of 94.31 per cent of the shares in ADDvise, extends the acceptance period and intends to initiate compulsory redemption and promote delisting

Amplex AB has secured ownership and control of approximately 94.31% of share capital and 94.32% of votes in ADDvise Group AB after its cash offer (increased to SEK 1.72 per A/B share and SEK 0.52 per warrant) was declared unconditional, and it now plans to initiate compulsory redemption and seek delisting from Nasdaq First North Premier Growth Market. At the end of the acceptance period (23 Jan 2026) Amplex held 21,568,131 class A and 550,018,863 class B shares; the acceptance period has been extended to 17 Feb 2026 with settlement for tenders expected around 24 Feb 2026 for the extended period. Advisors are Nordea (financial) and Linklaters (legal).

Analysis

Market structure: Amplex (acquirer) is the clear direct winner — control >94% compresses public float to ~5–6%, removes liquidity and creates a hard floor at SEK 1.72/share (warrants SEK 0.52). Remaining minority holders gain immediate liquidity if they tender; listed peers in Swedish/Nordic small‑cap life‑science may see 1–3% index-weight rebalancing and a 10–30% relative intraday volatility spike as index providers and ETF managers adjust. Pricing power shifts are idiosyncratic (private control), not sector‑wide, but reduced comparables and thinner market depth increase trading impact for similar microcaps.

Risk assessment: Tail risks include minority litigation or cross‑border payment/settlement delays that could postpone cash-out by 1–6 months, and regulatory hurdles to compulsory redemption (low probability but >0). Immediate window risks: market freezes, trading bans or nominee restrictions before Feb 17 (acceptance deadline) and settlement (expected Feb 24). Hidden dependencies: outstanding warrants, nominee custody rules and non‑Swedish holders' inability to tender could create residual fractional value post squeeze‑out.

Trade implications: Primary arb — buy ADDvise shares/warrants trading materially below SEK 1.72 and tender before Feb 17; with settlement expected Feb 24 this is a ~1‑4 week event trade. If direct access is restricted, hedge via short exposure to Nordic small‑cap life‑science (e.g., XACT Norden) or buy 1‑month put spreads to protect 1–3% portfolio tilt. Exit at settlement (cash receipt) or immediately on deal adverse news (extension beyond Mar 31).

Contrarian angles: Consensus treats the deal as done; missing is sequencing risk — warrants or foreign holder restrictions could leave a tiny public stub that retains value or litigation risk, creating asymmetric downside if market assumes immediate cash. The market may underprice delay risk (even a one‑month delay at 0% interest is an opportunity cost); historical Swedish squeeze‑outs mostly settle within 1–3 months but exceptions exist and can carry 50–300bps funding/ FX/custody costs for foreign holders.

Key Decisions for Investors

• If you can acquire ADDvise Group AB shares or TO1 warrants on market: establish a tactical long equal to 1–2% NAV only if midpoint price ≤ SEK 1.66 for shares or ≤ SEK 0.50 for warrants (implied gross arbitrage ≥3.6% to 1.72/0.52). Tender by Feb 17 and plan to exit on settlement around Feb 24; cap position size to limit name risk and set review if settlement extends beyond Mar 31.
• If direct access is blocked or illiquid: reduce exposure to Nordic small‑cap life‑science by 2–4% notional and initiate a short position in XACT Norden ETF (or equivalent) sized to offset ~50–100 bps sector‑specific liquidity risk over the next 1–3 months.
• Use options to hedge/express view: buy 1‑month ATM put and sell 1‑month 10% OTM put on XACT Norden (ratio 1:1) to create a protective put spread — target cost <0.6% notional and keep for 4–6 weeks; close on settlement or if ETF vol >25% intraday.
• Set micro‑alerts (trade tickets) to act on catalysts: (A) Jan 30 and Feb 24 settlement notices — buy weakness up to 2% more if spread to offer >3% and no legal flags; (B) any announcement of compulsory redemption start — trim longs if Amplex raises consideration above SEK 1.80 or if litigation is initiated, exit within 48 hours.